Educational Symposium
Diagnosis and Treatment of Hypocalcemia, Hypercalciuria, Nephrocalcinosis, and Kidney Stones
October 24, 2026 | 12:45 PM - 01:45 PM
Location: TBD Room, Hyatt Regency Denver
Session Description
Hypocalcemia has both genetic and acquired causes. This symposium focuses on genetic and acquired causes of hypoparathyroidism, including autosomal dominant hypocalcemia type 1 (ADH1), an underrecognized genetic condition. Experts review the pathophysiology of hypocalcemia and its complications and discuss common standard-of-care approaches, their risks, and strategies to minimize unintended treatment-related effects, such as nephrolithiasis and nephrocalcinosis.
Seating is limited and available on a first-come, first-served basis to fully paid Annual Meeting participants. Doors open approximately 15 minutes prior to each symposium. When a room reaches capacity, ASN will shut down access to the room. No other participants will be allowed to enter the room, regardless of the number of participants who exit the room during the activity.
Support is provided by an educational grant from BridgeBio Pharma, Inc.
Learning Objective(s)
- Describe the causes of hypocalcemia
- List the treatment strategies for acquired and genetic causes of hypoparathyroidism
- Compare the benefits and risks of standard and novel treatment strategies for hypoparathyroidism
Learning Pathway(s)
- Bones‚ Stones‚ and Mineral Metabolism
- CKD Non-Dialysis
Moderator
Presentations
- Introduction
12:45 PM - 12:55 PM
- Genetic Causes of Hypercalciuria, Nephrolithiasis, and Nephrocalcinosis
12:55 PM - 01:15 PM
- Pathophysiology of Hypocalcemia and Treatment Strategies
01:15 PM - 01:35 PM
- Q&A
01:35 PM - 01:45 PM